$PBH (Prestige Brands Holdings, Inc.)

$PBH {{ '2016-05-12T11:43:30+0000' | timeago}} • Announcement

$PBH, which markets over-the-counter healthcare and household cleaning products, reported a lower 4Q16 profit, mainly hurt by expenses, even as revenue rose 9% to $207.9MM. Latest quarter earnings were $13.9MM, or $0.26 per share, compared to $23.8MM, or $0.45 per share a year ago. Other expenses rose 72% while opex rose 9%.

$PG {{ '2017-10-20T19:57:21+0000' | timeago}} • Webcast

$PG still expects majority of EPS growth for 2018 to be driven by operating and earnings growth. The 1Q18 was a little bit more challenging, due to run up of commodity cost and the impact of the natural disasters. The productivity savings will build as $PG grows through the fiscal year and will also began annualizing pricing reductions investment.

$PG {{ '2017-10-20T19:46:37+0000' | timeago}} • Webcast

$PG expects to grow China Baby Care sales this fiscal year and return Pampers to share growth which would mark a significant turnaround. $PG continues to build share in ecommerce in China. $PG grew ecommerce sales about 60% in 1Q18 and a market growing around 50% with 7 out of 10 categories holding growing online market share.

$PG {{ '2017-10-20T19:43:52+0000' | timeago}} • Webcast

For FY18, $PG planned to deliver another year of 90% or better free cash flow productivity. This includes capital expenditures of 5-5.5% of sales. $PG continues its strong track record of cash return to shareholders. $PG expects to pay nearly $7.5Bil in dividends and repurchase $4-7Bil of its shares in FY18.

$PG {{ '2017-10-20T19:38:31+0000' | timeago}} • Webcast

$PG's results for 1Q18 includes about a 30 basis point impacts from the earthquake in Mexico and hurricanes in Texas to Gulf Coast and Puerto Rico. They also include a 40 basis point impact from the combination of U.S. pricing investments and discontinued brands of product forms. $PG said all of these impacts will dissipate as the year progresses.

$PG {{ '2017-10-20T12:44:20+0000' | timeago}} • Infographic

$PG The Procter & Gamble Co. Earnings AlphaGraphic: Q1 2018 Highlights

$CELG {{ '2017-10-20T12:40:12+0000' | timeago}} • Announcement

$CELG disclosed in an SEC filing that it expects to incur a pretax charge to earnings for 4Q17 in the range of $300-500MM ($0.27-0.45 per diluted share after tax) in connection with its decision to stop the two trials for Crohn's disease. Celgene also added that it would require to pay half of this charge in cash.

$PG {{ '2017-10-20T11:47:55+0000' | timeago}} • Announcement

$PG maintained its core EPS growth expectation of 5-7% versus FY17 Core EPS of $3.92. This is despite over $100MM of incremental commodity cost headwinds resulting from the hurricanes that impacted the Gulf Coast in September. All-in GAAP EPS are expected to decrease 26-28% versus 2017 GAAP EPS of $5.59.

$PG {{ '2017-10-20T11:45:58+0000' | timeago}} • Announcement

$PG maintained its guidance for organic sales growth in the range of 2-3% for FY18. The company estimates all-in sales growth of about 3% for FY18, which includes a neutral to half-a-percentage-point benefit to sales growth from the combined impacts of foreign exchange, acquisitions and divestitures.

$PG {{ '2017-10-20T11:44:44+0000' | timeago}} • Announcement

$PG's gross margin for 1Q18 decreased 40 basis points. On a currency-neutral basis, core gross margin fell 10 points as 150 points of productivity savings were more than offset by 70 points of commodity cost rises, 50 points of unfavorable geographic and product mix and 40 points of product reinvestments and other impacts.

$PG {{ '2017-10-20T11:41:13+0000' | timeago}} • Announcement

$PG's Baby, Feminine and Family Care segment organic sales for 1Q18 declined 1% from the prior year. Baby Care organic sales decreased mid-single digits due in part to competitive activity in Europe and a decline in China Baby Care shipments due primarily to wholesaler inventory run-down ahead of new innovation shipments.

$PG {{ '2017-10-20T11:40:58+0000' | timeago}} • Announcement

$PG's Health Care segment organic sales for 1Q18 rose 1%. Oral Care organic sales increased low single digits behind product innovation on power toothbrushes and toothpaste and increased marketing support. Personal Health Care organic sales slid low single digits on lower volume.

$PG {{ '2017-10-20T11:40:39+0000' | timeago}} • Announcement

$PG's grooming segment organic sales for 1Q18 fell 6% on lower sales in Shave Care. Organic sales slid high single digits in Shave Care due to price reductions in the U.S. and negative product mix. Organic sales rose double digits in Appliances on increased volume from the continued success of innovation on Braun male styling and mid-tier shavers.

$PG {{ '2017-10-20T11:40:23+0000' | timeago}} • Announcement

$PG's beauty segment organic sales for 1Q18 increased 5% from a year ago. Organic sales were up double digits in Skin & Personal Care on growth in China, including the continued acceleration of the super-premium SK-II brand. Organic sales increased low single digits in Hair Care on increased pricing across regions behind product innovation.

$PG {{ '2017-10-20T11:40:11+0000' | timeago}} • Announcement

$PG reported a 5% rise in 1Q18 earnings on lower interest expense, higher interest income and a rise in non-operating income. Net income grew to $2.85Bil or $1.06 per share from $2.71Bil or $0.96 per share last year. Net sales rose 0.8% to $16.65Bil. Core EPS increased to $1.09 from $1.03. Organic sales rose 1% on higher shipment volume.

$ISRG {{ '2017-10-19T21:40:26+0000' | timeago}} • Announcement

Worldwide da Vinci procedures grew approx. 15% in 3Q17 as $ISRG shipped 169 da Vinci Surgical Systems during the quarter. With $TRXC already in its sight, Intuitive Surgical will also be eyeing $MDT with much more concern as Medtronic is set to roll out its surgical robot system next year.

$ISRG {{ '2017-10-19T21:22:14+0000' | timeago}} • Announcement

Amidst concern over an emerging competition for its da Vinci Surgical Systems, $ISRG posted its 3Q17 results where revenue increased 18% and profit grew 41%. Recently, the US FDA has shown the green light for $TRXC to market its Senhance Surgical Robotic System, the first system since 2010 to compete head-to-head against $ISRG's da Vinci system.

$CELG {{ '2017-10-19T21:12:44+0000' | timeago}} • Announcement

$CELG said that it will stop the two trials for treating the Crohn's disease (a chronic inflammatory bowel disease), following an recommendation of the Data Monitoring Committee. No safety signals were identified during a recent interim futility analysis. Celgene added that the third trial will not be initiated at this time.

$JNJ {{ '2017-10-19T14:38:55+0000' | timeago}} • Announcement

$JNJ has declared a cash dividend for 4Q17 of $0.84 per share on its common stock. The dividend is payable on Dec 12, 2017 to shareholders as on Nov 28, 2017.

$JNJ {{ '2017-10-17T19:25:16+0000' | timeago}} • Webcast

$JNJ said, "The key factor to Remicade being successful is physicians and patients have a high confidence in it based on experience that they don't want to switch to an alternative." The company was responding to a question on rival $PFE's lawsuit against it for allegedly using unfair means to protect Remicade from competitors.

$JNJ {{ '2017-10-17T19:18:23+0000' | timeago}} • Webcast

$JNJ said sale of its blockbuster drug Remicade, used in the treatment of rheumatoid-arthritis declined 7.6% to $1.6Bil in 3Q17, hurt by competition from cheaper alternatives called biosimilars. The pharma giant said it has reduced Remicade's price, in view of tight competition in the market.

Recent Transcripts

PG (The Procter & Gamble Company)
Friday, October 20 2017 - 12:30pm
JNJ (Johnson & Johnson)
Tuesday, October 17 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
ACET (Aceto Corp.)
Friday, August 25 2017 - 1:00pm
MDCO (The Medicines Company)
Wednesday, August 9 2017 - 12:30pm
OMER (Omeros Corporation)
Tuesday, August 8 2017 - 8:30pm
VICL (Vical Incorporated)
Tuesday, August 8 2017 - 4:00pm
TXMD (TherapeuticsMD, Inc.)
Thursday, August 3 2017 - 8:30pm
CLX (The Clorox Company)
Thursday, August 3 2017 - 5:30pm
CHD (Church & Dwight Co. Inc.)
Thursday, August 3 2017 - 2:00pm
SYN (Synthetic Biologics Inc.)
Thursday, August 3 2017 - 12:30pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
PBH (Prestige Brands Holdings, Inc.)
Thursday, August 3 2017 - 12:30pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
PFE (Pfizer Inc.)
Tuesday, August 1 2017 - 2:00pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm
CL (Colgate-Palmolive Co.)
Friday, July 21 2017 - 3:00pm
JNJ (Johnson & Johnson)
Tuesday, July 18 2017 - 12:30pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm

AlphaGraphics you may like